前列地尔注射液联合杏丁注射液治疗慢性肾脏病4期临床研究

A clinical study on treating chronic kidney disease in IV stage with Alprostadil injection plus the Xingding injection

目的:观察前列地尔注射液联合杏丁注射液治疗慢性肾脏病(CKD)4期的临床疗效。方法:将65例CKD 4期患者随机分为治疗组(32例)和对照组(33例)。对照组采用常规治疗,治疗组在对照组治疗基础上加用前列地尔注射液与杏丁注射液联合治疗,疗程为2周。对比两组治疗前后血肌酐(Scr)、尿素氮(BUN)、内生肌酐清除率(Ccr)及24h尿蛋白定量(24h UP)水平及总体疗效。结果:(1)治疗组有效率明显高于对照组,差异有统计学意义(P<0.01);(2)治疗组治疗后血Scr、BUN、24h UP显著降低,Ccr显著上升,比较差异有统计学意义(P<0.05);对照组治疗前后Scr、BUN、Ccr、24h UP则无明显变化,比较差异无统计学意义(P>0.05);(3)两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:前列地尔注射液联合杏丁注射液治疗CKD 4期疗效显著,明显改善了肾功能,延缓了慢性肾脏病的进展,且安全性较好,值得临床推广运用。

Objective To observe the efcacy of Alprostadil and the Xingding injection on CKD in IV stage. Methods： 65 patients were randomly divided into the treatment group （32 cases） and the control group （33 cases）. The control group received conventional treatment; while the treatment group received Alprostadil with the Xingding injection, for 2 weeks. Results： The total efciency in the treatment group was significantly higher than the control group （P〈0.01）. Blood Scr, BUN, 24hUP were significantly decreased after treatment, and Ccr was increased signifcantly in the treatment group （P〈0.05）. There was no signifcant diference in Scr, BUN, Ccr and 24hUP between before and after treatment in the control group （P〉0.05）. There was no signifcant diference in the incidence of adverse reactions between two groups （P〉0.05）. Conclusion： Alprostadil and the Xingding injection on chronic kidney disease in IV stage was efective, by signifcantly improving renal function and delaying the progress of CKD, with security, and was worthy of clinical application.